Initial treatment of thyrotoxic Graves' disease with methimazole: a randomized trial comparing different dosages.
We evaluated the efficacy of different doses of methimazole (MMI) as the initial therapy for Graves' disease. Fourteen patients were treated with 15 mg/die of the drug (group A) and 14 with 30 mg/die (group B). Blood samples for T3, T4, FT3 and FT4 were obtained before beginning therapy, every 48 h during the first 12 days and on the 45th day of treatment. All these hormonal parameters fell significantly from the 2nd day of therapy in both groups. All the patients, except for one in group B, had normal or subnormal levels of thyroidal hormones on the 45th day of treatment. The comparison between the two groups of regression coefficients over the first 12 days showed no significant differences. The absolute decrease of each examined parameter on day 12 was positively correlated with the relevant pretreatment value. These results demonstrate that doses of MMI (15 mg/die) much lower than those commonly recommended are able to rapidly control thyroidal overproduction as effectively as 30 mg/die.
Messina
M
M
Milani
P
P
Gentile
L
L
Monaco
A
A
Brossa
C
C
Porta
M
M
Camanni
F
F
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D005260:Female; D006111:Graves Disease / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008713:Methimazole / Q000008:administration & dosage* / Q000627:therapeutic use; D008875:Middle Aged; D011897:Random Allocation; D013963:Thyroid Hormones / Q000097:blood
D013963:Thyroid Hormones; D008713:Methimazole